REFERENCES
- Belardelli F., Ferrantini M. Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol. 2002; 23(4)201–208, [INFOTRIEVE], [CSA], [CSA]
- Kiessling R., Wasserman K., Horiguchi S., Kono K., Sjoberg J., Pisa P., Petersson M. Tumor-induced immune dysfunction. Cancer Immunol. Immunother. 1999; 48(7)353–362, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA], [CSA]
- Rhines L. D., Sampath P., DiMeco F., Lawson H. C., Tyler B. M., Hanes J., Olivi A., Brem H. Local immunotherapy with interleukin-2 delivered from biodegradable polymer microspheres combined with interstitial chemotherapy: a novel treatment for experimental malignant glioma. Neurosurgery 2003; 52(4)872–880, [INFOTRIEVE], [CROSSREF], [CSA], [CSA]
- Shakhar G., Ben-Eliyahu S. Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients?. Ann. Surg. Oncol. 2003; 10(8)972–992, [INFOTRIEVE], [CROSSREF], [CSA], [CSA]
- Zagozdzon R., Golab J., Stoklosa T., Giermasz A., Nowicka D., et al. Effective chemo-immunotherapy of L1210 leukemia in vivo using interleukin-12 combined with doxorubicin but not with cyclophosphamide, paclitaxel or cisplatin. Int. J. Cancer 1998; 77: 720–727, [INFOTRIEVE], [CROSSREF], [CSA], [CSA]
- Robertson M. J., Ritz J. Interleukin 12: basic biology and potential applications in cancer treatment. Oncologist 1996; 1(1 & 2)88–97, [INFOTRIEVE], [CSA], [CSA]
- Robertson M. J., Pelloso D., Abonour R., Hromas R. A., Nelson R. P., Wood L., Jr., Cornetta K. Interleukin 12 immunotherapy after autologous stem cell transplantation for hematological malignancies. Clin. Cancer. Res 2002; 8(11)3383–3393, [INFOTRIEVE], [CSA], [CSA]
- Roy E. J., Gawlick U., Orr B. A., Rund L. A., Webb A. G., Kranz D. M. IL-12 treatment of endogenously arising murine brain tumors. J. Immunol 2001; 165: 7293–7399, [CSA], [CSA]
- Melero I., Mazzolini G., Narvaiza I., Qian C., Chen L., Prieto J. IL-12 gene therapy for cancer: in synergy with other immunotherapies. Immunol. Today 2001; 22: 113–115, [CSA], [CSA]
- Tzai T. S., Shiau A. L., Wu C. L., Tsai Y. S. Postoperative administration of interleukin-12 significantly enhances the anti-tumor immune response of MBT-2 bladder cancer bearing mice. Proc. Natl. Sci. Counc. Repub. China B 2000; 24(2)56–62, [INFOTRIEVE], [CSA], [CSA]
- Hara I., Horikawa T., Fujii M., Kurimoto M., Kamidono S., Ichihashi M. Antitumor effects on mouse melanoma elicited by local secretion of interleukin-12 and their enhancement by treatment with interleukin-18. Cancer. Invest. 2000; 18: 206–213, [INFOTRIEVE], [CSA], [CSA]
- Mortarini R., Borri A., Tragni G., Bersani I., Vegetti C., Bajetta E., Pilotti S., Cerundolo V., Anichini A. Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12. Cancer. Res. 2000; 60(13)3559–3568, [INFOTRIEVE], [CSA], [CSA]
- Ma X. TNF-alpha and IL-12: a balancing act in macrophage functioning. Microbes Infect. 2001; 3(2)121–129, [INFOTRIEVE], [CROSSREF], [CSA], [CSA]
- Mullins D. W., Burger C. J., Elgert K. D. Paclitaxel enhances macrophage IL-12 production in tumor-bearing hosts through nitric oxide. J. Immunol. 1999; 162: 6811–6818, [INFOTRIEVE], [CSA], [CSA]
- Mullins D. W., Koci M. D., Burger C. J., Elgert K. D. Interleukin-12 overcomes paclitaxel-mediated suppression of T-cell reactivity. Immunopharmacol Immunotoxicol 1998; 20: 473–492, [INFOTRIEVE], [CSA], [CSA]
- Donaldson K. L., Goolsby G. L., Wahl A. F. Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle. Int. J. Cancer. 1994; 57(6)847–855, [INFOTRIEVE], [CSA], [CSA]
- Fuchs D. A., Johnson R. K. Cytologic evidence that taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison. Cancer Treat Rep. 1978; 62: 1219–1222, [INFOTRIEVE], [CSA], [CSA]
- Rowinsky E. K., Donehower R. C., Jones R. J., Tucker R. W. Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res. 1988; 48: 4093–4100, [INFOTRIEVE], [CSA], [CSA]
- Chuang L. T., Lotzova E., Heath J., Cook K. R., Munkarah A., Morris M., Wharton J. T. Alteration of lymphocyte microtubule assembly, cytotoxicity, and activation by the anticancer drug taxol. Cancer Res. 1994; 54: 1286–1291, [INFOTRIEVE], [CSA], [CSA]
- Elgert K. D., Farrar W. L. Suppressor cell activity in tumor-bearing mice. I. Dualistic inhibition by suppressor T lymphocytes and macrophages. J. Immunol. 1978; 120: 1345–1353, [INFOTRIEVE], [CSA], [CSA]
- Alleva D. G., Burger C. J., Elgert K. D. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-α production. Role of tumor-derived IL-10, TGF-β, and prostaglandin E2. J Immunol. 1994; 153: 1674–1686, [INFOTRIEVE], [CSA], [CSA]
- Trinchieri G. Immunobiology of interleukin-12. Immunol Res. 1998; 17: 269–278, [INFOTRIEVE], [CSA], [CSA]
- Green L. C., Wagner D. A., Glogowski J., Skipper P. L., Wishnok J. S., Tannenbaum S. R. Analysis of nitrate, nitrite, [15N]nitrate in biological fluids. Anal Biochem. 1982; 126: 131–138, [INFOTRIEVE], [CROSSREF], [CSA], [CSA]
- Mullins D. W., Burger C. J., Elgert K. D. Tumor growth modulates macrophage nitric oxide production following paclitaxel administration. Int. J. Immunopharmacol. 1998; 20: 537–551, [INFOTRIEVE], [CROSSREF], [CSA], [CSA]
- Seder R. A., Gazzinelli R., Sher A., Paul W. E. Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. Proc. Natl. Acad. Sci. USA. 1993; 90: 10188–10192, [INFOTRIEVE], [CROSSREF], [CSA], [CSA]
- Cahan M. A., Walter K. A., Colvin O. M., Brem H. Cytotoxicity of taxol in vitro against human and rat malignant brain tumors. Cancer Chemother Pharmacol. 1994; 33: 441–444, [INFOTRIEVE], [CSA], [CSA]
- Liebmann J. E., Cook J. A., Lipschultz C., Teague D., Fisher J., Mitchell J. B. Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. Br. J. Cancer. 1993; 68(6)1104–1109, [INFOTRIEVE], [CSA], [CSA]
- Milas L., Hunter N. R., Kurdoglu B., Mason K. A., Meyn R. E., Stephens L. C., Peters L. J. Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol. Cancer Chemother Pharmacol. 1995; 35: 297–303, [INFOTRIEVE], [CSA], [CSA]
- Bishop J. F., Dewar J., Toner G. C., Tattersall M. H., Olver I. N., Ackland S., Kennedy I., Goldstein D., Gurney H., Walpole E., Levi J., Stephenson J. Paclitaxel as first-line treatment for metastatic breast cancer. Oncology. 1997; 11: 19–23, [INFOTRIEVE], [CSA], [CSA]
- Chougnet C., Shearer G. M. Potential clinical applications of interleukin-12. Curr. Opin. Hematol. 1996; 3: 216–222, [INFOTRIEVE], [CSA], [CSA]
- Trinchieri G., Gerosa F. Immunoregulation by interleukin-12. J. Leukoc. Biol. 1996; 59: 505–511, [INFOTRIEVE], [CSA], [CSA]
- Hiscox S., Jiang W. G. Interleukin-12, an emerging anti-tumor cytokine. In Vivo. 1997; 11: 125–132, [INFOTRIEVE], [CSA], [CSA]
- Mullins D. W., Walker T. M., Burger C. J., Elgert K. D. Taxol-mediated changes in fibrosarcoma-induced macrophage function: modulation of antitumor activities. Cancer Immunol Immunother. 1997; 45: 20–28, [INFOTRIEVE], [CROSSREF], [CSA], [CSA]
- Alzona M., Jack H. -M., Fisher R. I., Ellis T. M. IL-12 activates IFN-gamma production through the preferential activation of CD30+ T cells. J Immunol. 1995; 154: 9–16, [INFOTRIEVE], [CSA], [CSA]
- Gollob J. A., Mier J. W., Veenstra K., McDermott D. F., Clancy D., Clancy M., Atkins M. B. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-γ induction is associated with clinical response. Clin Cancer Res. 2000; 6(5)1678–1692, [INFOTRIEVE], [CSA], [CSA]
- Albina J. E., Henry W. L., Jr. Suppression of lymphocyte proliferation through the nitric oxide synthesizing pathway. J. Surg. Res. 1991; 50: 403–409, [INFOTRIEVE], [CROSSREF], [CSA], [CSA]
- Cuthbert J. A., Shay J. W. Microtubules and lymphocyte responses: effect of colchicine and taxol on mitogen-induced human lymphocyte activation and proliferation. J. Cell. Physiol. 1983; 116: 127–134, [INFOTRIEVE], [CROSSREF], [CSA], [CSA]
- Brown D. L., Little J. E., Chaly N., Schweitzer I., Paulin-Levasseur M. Effects of taxol on microtubule organization in mouse splenic lymphocytes and on response to mitogenic stimulation. Eur. J. Cell. Biol. 1985; 37: 130–139, [INFOTRIEVE], [CSA], [CSA]
- Roy C., Prased K. V., Reuhl K. R., Little J. E., Valentine B. K., Brown D. L. Taxol protects the microtubules of concanavalin-A-activated lymphocytes from disassembly by methylmercury, but DNA synthesis is still inhibited. Exp. Cell. Res. 1991; 195: 345–352, [INFOTRIEVE], [CROSSREF], [CSA], [CSA]
- Roy C., Chaly N., Brown D. L. Taxol-induced reorganization of the microtubule system in murine splenic lymphocytes inhibits response to allogeneic cells but not to concanavalin A. Biochem. Cell. Biol. 1988; 66: 389–395, [INFOTRIEVE], [CSA], [CSA]
- Chuang L. T., Lotzova E., Cook K. R., Cristoforoni P., Morris M., Wharton J. T. Effect of new investigational drug taxol on oncolytic activity and stimulation of human lymphocytes. Gynecol. Oncol. 1993; 49(3)291–298, [INFOTRIEVE], [CROSSREF], [CSA], [CSA]
- Manthey C. L., Perera P. -Y., Salkowski C. A., Vogel S. N. Taxol provides a second signal for murine macrophage tumorcidical activity. J. Immunol. 1994; 152: 825–831, [INFOTRIEVE], [CSA], [CSA]
- Mullins D. W., Alleva D. G., Burger C. J., Elgert K. D. Taxol, a microtubule-stabilizing antineoplastic agent, differentially regulates normal and tumor-bearing host macrophage nitric oxide production. Immunopharmacology. 1997; 37: 63–73, [INFOTRIEVE], [CROSSREF], [CSA], [CSA]
- van Herpen C. M., van der Laak J. A., de Vries I. J., van Krieken J. H., de Wilde P. C., Balvers M. G., Adema G. J., De Mulder P. H. Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor. Clin Cancer Res. 2005; 11(5)1899–1909, [INFOTRIEVE], [CROSSREF], [CSA], [CSA]
- Campone M., Fumoleau P. Weekly administration of paclitaxel in the treatment of metastatic breast cancer: from rational to practice. Bull. Cancer. 2002; 89(3)275–282, [INFOTRIEVE], [CSA], [CSA]
- Miller K. D. E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. Clin. Breast Cancer. 2003; 3(6)421–422, [INFOTRIEVE], [CSA], [CSA]
- Gajewski T. F. Integrating IL-12 into therapeutic cancer vaccines. Cancer Chemother Biol. Response Modif. 2002; 20: 343–349, [INFOTRIEVE], [CSA], [CSA]
- Janat-Amsbury M. M., Yockman J. W., Lee M., Kern S., Furgeson D. Y., Bikram M., Kim S. W. Local, non-viral IL-12 gene therapy using a water soluble lipopolymer as carrier system combined with systemic paclitaxel for cancer treatment. J. Control. Release. 2005; 101(1–3)273–285, [INFOTRIEVE], [CROSSREF], [CSA], [CSA]
- Janat-Amsbury M. M., Yockman J. W., Lee M., Kern S., Furgeson D. Y., Bikram M., Kim S. W. Combination of local, nonviral IL12 gene therapy and systemic paclitaxel treatment in a metastatic breast cancer model. Mol. Ther. 2004; 9(6)829–836, [INFOTRIEVE], [CROSSREF], [CSA], [CSA]